Genzyme Pompe Program Update--FDA Approves Lumizyme
On May 24, 2010 the Food and Drug Administration (FDA) approved Lumizyme for treatment of “patients 8 years and older with late (non-infantile) onset Pompe disease who do not have evidence of cardiac hypertrophy.”
For more information on the approval, and how to access treatment please read
Genzyme’s Pompe Program Update.
© International Pompe Association
Secretariat (NL): +31 35 5480461